Perceptive Advisors as of March 31, 2013
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 66 positions in its portfolio as reported in the March 2013 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Infinity Pharmaceuticals (INFIQ) | 18.9 | $158M | 3.2M | 48.47 | |
| Aegerion Pharmaceuticals | 17.3 | $144M | 3.6M | 40.34 | |
| Sarepta Therapeutics (SRPT) | 13.3 | $110M | 3.0M | 36.96 | |
| Neurocrine Biosciences (NBIX) | 6.4 | $54M | 4.4M | 12.15 | |
| Acelrx Pharmaceuticals | 3.1 | $26M | 5.0M | 5.16 | |
| Capital Senior Living Corporation | 2.7 | $22M | 844k | 26.43 | |
| EXACT Sciences Corporation (EXAS) | 2.5 | $21M | 2.2M | 9.80 | |
| Shire | 2.3 | $19M | 211k | 91.36 | |
| ViroPharma Incorporated | 2.3 | $19M | 756k | 25.16 | |
| Celgene Corporation | 2.2 | $18M | 155k | 115.92 | |
| Questcor Pharmaceuticals | 2.1 | $18M | 546k | 32.54 | |
| Hca Holdings (HCA) | 1.9 | $15M | 380k | 40.63 | |
| Repros Therapeutics | 1.6 | $14M | 853k | 16.10 | |
| Gilead Sciences (GILD) | 1.6 | $14M | 276k | 48.94 | |
| Regeneron Pharmaceuticals (REGN) | 1.4 | $12M | 65k | 176.40 | |
| Chelsea Therapeutics International | 1.4 | $12M | 5.6M | 2.04 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.3 | $11M | 200k | 54.97 | |
| Covidien | 1.3 | $11M | 157k | 67.84 | |
| Synta Pharmaceuticals | 1.1 | $9.4M | 1.1M | 8.60 | |
| Astex Pharmaceuticals | 1.1 | $9.4M | 2.1M | 4.47 | |
| Neptune Technologies Bioreso | 1.1 | $8.9M | 3.5M | 2.52 | |
| Conceptus | 1.1 | $8.7M | 362k | 24.15 | |
| Athersys | 0.9 | $7.5M | 4.5M | 1.68 | |
| Novartis (NVS) | 0.9 | $7.4M | 104k | 71.24 | |
| Biogen Idec (BIIB) | 0.9 | $7.2M | 38k | 192.61 | |
| PROLOR Biotech | 0.8 | $7.0M | 1.4M | 5.06 | |
| Lexicon Pharmaceuticals | 0.8 | $7.0M | 3.2M | 2.18 | |
| ISIS Pharmaceuticals | 0.6 | $5.1M | 300k | 16.94 | |
| Cutera (CUTR) | 0.6 | $4.9M | 377k | 13.00 | |
| Tesaro | 0.5 | $4.3M | 198k | 21.96 | |
| Alnylam Pharmaceuticals (ALNY) | 0.5 | $3.8M | 157k | 24.37 | |
| Newlink Genetics Corporation | 0.4 | $3.7M | 300k | 12.27 | |
| Dyax Corp | 0.4 | $3.3M | 752k | 4.36 | |
| Supernus Pharmaceuticals (SUPN) | 0.4 | $3.3M | 583k | 5.62 | |
| NPS Pharmaceuticals | 0.4 | $3.1M | 302k | 10.21 | |
| Cempra | 0.4 | $3.0M | 450k | 6.75 | |
| InterMune | 0.3 | $2.7M | 300k | 9.05 | |
| Anthera Pharmaceuticals | 0.3 | $2.3M | 3.5M | 0.66 | |
| Neostem (NBS) | 0.3 | $2.3M | 3.3M | 0.68 | |
| Celsion Corporation | 0.2 | $1.8M | 1.7M | 1.05 | |
| Immunomedics | 0.2 | $1.8M | 739k | 2.41 | |
| INC Ventrus Biosciences | 0.2 | $1.7M | 560k | 2.99 | |
| Tekmira Pharmaceuticals Corporation | 0.2 | $1.5M | 320k | 4.74 | |
| BioMed Realty Trust | 0.2 | $1.4M | 63k | 21.60 | |
| Alkermes (ALKS) | 0.1 | $1.2M | 50k | 23.70 | |
| Vivus | 0.1 | $1.1M | 100k | 11.00 | |
| Champions Oncology | 0.1 | $1.1M | 1.8M | 0.60 | |
| XOMA CORP Common equity shares | 0.1 | $1.0M | 292k | 3.49 | |
| Mgc Diagnostics | 0.1 | $974k | 139k | 6.99 | |
| Achillion Pharmaceuticals | 0.1 | $875k | 100k | 8.75 | |
| HeartWare International | 0.1 | $884k | 10k | 88.40 | |
| Medivation | 0.1 | $818k | 18k | 46.74 | |
| Transgenomic | 0.1 | $800k | 2.0M | 0.40 | |
| Uroplasty | 0.1 | $716k | 288k | 2.49 | |
| Medgenics | 0.1 | $728k | 150k | 4.85 | |
| Rigel Pharmaceuticals | 0.1 | $680k | 100k | 6.80 | |
| Liposcience | 0.1 | $685k | 65k | 10.52 | |
| Celldex Therapeutics | 0.1 | $579k | 50k | 11.58 | |
| INSTRS INC Stemcells | 0.1 | $401k | 232k | 1.73 | |
| Sunesis Pharmaceuticals | 0.0 | $317k | 58k | 5.46 | |
| Myriad Genetics (MYGN) | 0.0 | $254k | 10k | 25.40 | |
| Emeritus Corporation | 0.0 | $278k | 10k | 27.80 | |
| ZIOPHARM Oncology | 0.0 | $183k | 100k | 1.83 | |
| RTI Biologics | 0.0 | $107k | 27k | 3.92 | |
| Neoprobe | 0.0 | $54k | 20k | 2.70 | |
| Combimatrix Corporation *w exp 05/01/ | 0.0 | $2.0k | 5.0k | 0.40 |
